UiPath (NYSE:PATH) PT Raised to $25.00

UiPath (NYSE:PATH) had its target price hoisted by equities researchers at Morgan Stanley from $17.00 to $25.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the healthcare company’s stock. Morgan Stanley’s target price points to a potential upside of 8.39% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Mizuho raised their price objective on shares of UiPath from $18.00 to $22.00 and gave the stock a “neutral” rating in a report on Friday, December 1st. Barclays lifted their price target on shares of UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a report on Friday. Needham & Company LLC lifted their price target on shares of UiPath from $25.00 to $30.00 and gave the company a “buy” rating in a report on Thursday. BMO Capital Markets lifted their price target on shares of UiPath from $19.00 to $24.00 and gave the company a “market perform” rating in a report on Friday, December 1st. Finally, Canaccord Genuity Group lifted their price target on shares of UiPath from $27.00 to $30.00 and gave the company a “buy” rating in a report on Friday. Nine analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $27.13.

UiPath Stock Up 1.4 %

NYSE PATH traded up $0.32 during midday trading on Thursday, hitting $23.07. The company had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. The firm has a fifty day simple moving average of $23.52 and a two-hundred day simple moving average of $20.70. The stock has a market cap of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97. UiPath has a fifty-two week low of $12.38 and a fifty-two week high of $27.87.

Insider Activity at UiPath

In other news, CFO Ashim Gupta sold 125,000 shares of the stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $22.59, for a total transaction of $2,823,750.00. Following the transaction, the chief financial officer now owns 858,148 shares in the company, valued at $19,385,563.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $23.12, for a total value of $4,624,000.00. Following the completion of the sale, the director now directly owns 429,418 shares in the company, valued at approximately $9,928,144.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ashim Gupta sold 125,000 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $22.59, for a total value of $2,823,750.00. Following the completion of the sale, the chief financial officer now owns 858,148 shares of the company’s stock, valued at $19,385,563.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 411,000 shares of company stock worth $9,418,670. Insiders own 31.03% of the company’s stock.

Institutional Trading of UiPath

Several institutional investors have recently added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC bought a new stake in shares of UiPath during the 4th quarter valued at $25,000. HighMark Wealth Management LLC bought a new stake in shares of UiPath during the 4th quarter valued at $27,000. Tyler Stone Wealth Management bought a new stake in shares of UiPath during the 2nd quarter valued at $28,000. Cypress Capital Management LLC WY bought a new stake in shares of UiPath during the 4th quarter worth $29,000. Finally, Fifth Third Bancorp lifted its position in shares of UiPath by 2,005.3% during the 3rd quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock worth $34,000 after buying an additional 1,905 shares during the last quarter. 59.04% of the stock is currently owned by institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.